Trial Profile
Randomized Phase II Trial of Temozolomide Versus Hyd-sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary) ; Dacarbazine; Temozolomide
- Indications Uveal melanoma
- Focus Therapeutic Use
- 07 Apr 2017 Status changed from active, no longer recruiting to completed.
- 01 Mar 2017 Results assess patient-reported HRQoL between study arms and subgroups of patients, published in the Journal of Cancer Research and Clinical Oncology
- 04 Dec 2016 Planned primary completion date changed from 1 Dec 2015 to 1 May 2016 as reported by ClinicalTrials.gov.